MedPage Today news story
The four-component meningococcal serogroup B vaccine (4CMenB; Bexsero) did not reduce gonorrhea incidence in high-risk men who have sex with men, according to a randomized trial.
The incidence rate ratio of gonorrhea was not significantly different over 2 years of follow-up between participants who received two doses of 4CMenB and those who received placebo, reported Kate Seib, PhD, of the Institute for Biomedicine and Glycomics at Griffith University in Southport, Australia.
Read the full news story here.
View all MedPage Today reports from CROI 2026
SEE ALSO:
- Infectious Disease Special Edition: 4CMenB vaccine does not prevent gonorrhea in high-risk men
View all Infectious Disease Special Edition reports from CROI 2026
View all Healio reports from CROI 2026
View all aidsmap reports from CROI 2026
Source : MedPage Today
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.